ELETRIPTAN HBR
Acute attack of migraine
Adult 18-65 yr Initially 40 mg, repeated if necessary after 2 hr. Max: 160 mg/day.
Severe hepatic or renal impairment, uncontrolled HTN, confirmed CHD including ischaemic heart disease peripheral vascular disease. History of CVA or transient ischaemic attack. Concomitant ergotamine, ergotamine derivatives (including methysergide), other 5-HT1 receptor agonists.
Not to be used in hemiplegic or basilar migraine.Elderly, renal impairement, pregnancy, lactation and children. Use in caution in drivers or machine operators.
Fatigue, somnolence, dizziness, nausea.
Erythromycin, ketoconazole, specific & potent CYP3A4 inhibitors eg itraconazole & clarithromycin.
Brand Name | Manufactured by |
---|---|
ELIPRAN | INTAS PHARMACEUTICALS LTD. |
ELIPRAN | INTAS PHARMACEUTICALS LTD. |
RELPAX | PFIZER LTD. |